Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 42

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 42
---
 our common stock on our behalf, the
Agent will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of the Agent will
be deemed to be underwriting commission or discounts. We have agreed to provide indemnification and contribution to the Agent against
certain civil liabilities, including liabilities under the Securities Act.

This offering pursuant to the Sales Agreement will terminate upon the
earlier of (1) the issuance and sales of all of our common stock subject to the Sales Agreement; and (2) the termination of the sales
agreement as permitted therein. We or the Agent may terminate the Sales Agreement at any time pursuant to the terms of the Sales Agreement.

The Agent and its affiliates may in the future provide various investment
banking and other financial services for us and our affiliates, for which services it may in the future receive customary fees. In addition,
in the ordinary course of its various business activities, the Agent and its affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans)
for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or
instruments of ours or our affiliates. The Agent or its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments. The Agent acted as the placement agent in connection with our May 2025
public offering and received compensation from us in connection therewith. Except as disclosed in this prospectus supplement, we have
no present arrangements with the Agent for any further services.

To the extent required by Regulation
M, the Agent will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus
supplement. This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and
conditions. A copy of the Sales Agreement is filed as an exhibit to the registration statement to which this prospectus supplement and
accompanying base prospectus are attached, and incorporated by reference in this prospectus supplement. This prospectus supplement and accompanying prospectus in electronic
format may be made available on a website maintained by the Agent and the Agent may distribute this prospectus electronically.

Our common stock is listed
on The Nasdaq Capital